Stein O, Stein Y
Department of Experimental Medicine and Cancer Research, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Arteriosclerosis. 1987 Nov-Dec;7(6):578-84. doi: 10.1161/01.atv.7.6.578.
The macrophage-like cell line, J774, and its variant, CT2, were used to study the effect of verapamil on metabolism of esterified cholesterol. The cells had been labelled with 3H-cholesterol for 24 hours and thereafter acetylated low density lipoprotein (LDL) or d less than 1.019 g/ml fraction of hypercholesterolemic rabbit plasma was added. After an additional 24 hours, 60% or 40% of the label, respectively, was recovered in esterified cholesterol in control dishes, but only 2% to 15%, in the presence of 50 microM verapamil. Enhancement of esterification of cellular 3H-cholesterol was also obtained by addition of liposomes with a cholesterol/phosphatidylcholine molar ratio of 2:1. This reaction was almost completely inhibited by compound 58-035, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, while addition of verapamil resulted in a dose-dependent partial inhibition which was evident after 4 hours. To determine whether the reduction in cholesterol esterification was due to a direct inhibition of ACAT or to an effect of verapamil on the transport of cholesterol to the site of ACAT activity, the cells were incubated with acetylated LDL labelled with 3H-cholesteryl ester, and the amount of uptake, lysosomal hydrolysis, and cytoplasmic reesterification was determined. In control cells and in cells exposed to the ACAT inhibitor, more than 98% of the 3H-cholesteryl ester taken up had been hydrolyzed. Reesterification of 3H-cholesterol was negligible in the presence of the ACAT inhibitor and amounted to 37.1% in control cells. When verapamil was present, reesterification of 3H-cholesterol to cholesteryl ester was only 4%, while the amount of 3H-cholesteryl ester hydrolyzed was 58% of that taken up.(ABSTRACT TRUNCATED AT 250 WORDS)
巨噬细胞样细胞系J774及其变体CT2被用于研究维拉帕米对酯化胆固醇代谢的影响。细胞先用3H-胆固醇标记24小时,然后加入乙酰化低密度脂蛋白(LDL)或高胆固醇血症兔血浆中密度小于1.019 g/ml的组分。再过24小时后,对照培养皿中分别有60%或40%的标记物在酯化胆固醇中回收,但在50 microM维拉帕米存在的情况下,仅为2%至15%。通过添加胆固醇/磷脂酰胆碱摩尔比为2:1的脂质体,也能增强细胞内3H-胆固醇的酯化。该反应几乎完全被酰基辅酶A:胆固醇酰基转移酶(ACAT)抑制剂化合物58-035抑制,而加入维拉帕米会导致剂量依赖性的部分抑制,4小时后即可明显看出。为了确定胆固醇酯化减少是由于直接抑制ACAT还是维拉帕米对胆固醇转运至ACAT活性位点的影响,将细胞与用3H-胆固醇酯标记的乙酰化LDL一起孵育,并测定摄取量、溶酶体水解量和细胞质再酯化量。在对照细胞和暴露于ACAT抑制剂的细胞中,摄取的3H-胆固醇酯中超过98%已被水解。在ACAT抑制剂存在的情况下,3H-胆固醇的再酯化可忽略不计,而在对照细胞中为37.1%。当存在维拉帕米时,3H-胆固醇再酯化为胆固醇酯的比例仅为4%,而水解的3H-胆固醇酯量为摄取量的58%。(摘要截短于250字)